The North America typhoid fever vaccines market is expected to reach US$ 182.71 million in 2027 from US$ 89.84 million in 2019. The market is estimated to grow with a CAGR of 9.6% from 2020-2027.
The growth of the market is driven by the factors such as, increase in number of Americans travelling to developing countries. However, risks associated with typhoid fever vaccines likely to have negative impact on the growth of the North America Typhoid Fever Vaccines market in the coming years.
Typhoid vaccination is not recommended on a routine basis; however, it is recommended for people traveling to places where typhoid fever is common. Therefore, an increase in the number of Americans traveling outside the North American region is likely to favor the growth of the market. As per the U.S. Commerce Department’s National Travel and Tourism Office, the number of U.S. citizens traveling outside the country for business and tourism increased by 6% in 2019, reaching a total of 93 million.
Furthermore, typhoid is more prevalent in Asian countries; as per the data by National Travel & Tourism Office, in 2019, around 7,886 thousand people traveled to Asia for business and leisure, which is a 5% increase than in 2018. Thus, an increasing number of US travelers to Asian countries is likely to demand typhoid vaccination.
Furthermore, North America is witnessing the growing number of COVID-19 cases, for instance, in the United States the number of cases has been increased to 1,895,507 with 108,79 deaths reported. Additionally, Mexico and Canada cases are also growing. Due to coronavirus spreading, many cities are shutting down causing treatments and doctor’s appointment cancellation. Supply chain disruptions associated with this pandemic situation will ultimately affect the sales of products for short period. Also, stay-at-home and shelter-in-place orders have resulted in decreased outpatient pediatric visits and fewer vaccine doses were administered, leaving children at risk for vaccine-preventable diseases. Therefore, it is likely to affect typhoid fever vaccines s market owing to above mention points.
Mexico Typhoid Fever Vaccines Market Revenue and Forecast to 2027 (US$ Mn)

- This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.
North America Typhoid Fever Vaccines – Market Segmentation
By Vaccine Type
- Live Attenuated Vaccine
- Capsular Polysaccharide Vaccines
- Conjugate Vaccine
- Others
By Route of Administration
- Oral
- Injectable
By Country
- US
- Canada
- Mexico
Company Profiles
- Sanofi
- GlaxoSmithKline plc
- Paxvax Inc
- Prokarium Ltd
- Scandinavian Biopharma
North America Typhoid Fever Vaccines Report Scope
Report Attribute | Details |
---|---|
Market size in 2019 | US$ 89.84 Million |
Market Size by 2027 | US$ 182.71 Million |
Global CAGR (2020 - 2027) | 9.6% |
Historical Data | 2017-2018 |
Forecast period | 2020-2027 |
Segments Covered |
By Vaccine Type
|
Regions and Countries Covered | North America
|
Market leaders and key company profiles |
- Historical Analysis (2 Years), Base Year, Forecast (7 Years) with CAGR
- PEST and SWOT Analysis
- Market Size Value / Volume - Global, Regional, Country
- Industry and Competitive Landscape
- Excel Dataset
Testimonials

I wish to appreciate your support and the professionalism you displayed in the course of attending to my request for information regarding to infectious disease IVD market in Nigeria. I appreciate your patience, your guidance, and the fact that you were willing to offer a discount, which eventually made it possible for us to close a deal. I look forward to engaging The Insight Partners in the future, all thanks to the impression you have created in me as a result of this first encounter.
DR CHIJIOKE ONYIA, MANAGING DIRECTOR, PineCrest Healthcare Ltd.
The Insight Partners delivered insightful, well-structured market research with strong domain expertise. Their team was professional and responsive throughout. The user-friendly website made accessing industry reports seamless. We highly recommend them for reliable, high-quality research services
Yukihiko Adachi CEO, Deep Blue, LLC.Reason to Buy
- Informed Decision-Making
- Understanding Market Dynamics
- Competitive Analysis
- Customer Insights
- Market Forecasts
- Risk Mitigation
- Strategic Planning
- Investment Justification
- Identifying Emerging Markets
- Enhancing Marketing Strategies
- Boosting Operational Efficiency
- Tracking Industry Innovations
- Aligning with Regulatory Trends
Yes! We provide a free sample of the report, which includes Report Scope (Table of Contents), report structure, and selected insights to help you assess the value of the full report. Please click on the "Download Sample" button or contact us to receive your copy.
Absolutely — analyst assistance is part of the package. You can connect with our analyst post-purchase to clarify report insights, methodology or discuss how the findings apply to your business needs.
Once your order is successfully placed, you will receive a confirmation email along with your invoice.
• For published reports: You’ll receive access to the report within 4–6 working hours via a secured email sent to your email.
• For upcoming reports: Your order will be recorded as a pre-booking. Our team will share the estimated release date and keep you informed of any updates. As soon as the report is published, it will be delivered to your registered email.
We offer customization options to align the report with your specific objectives. Whether you need deeper insights into a particular region, industry segment, competitor analysis, or data cut, our research team can tailor the report accordingly. Please share your requirements with us, and we’ll be happy to provide a customized proposal or scope.
The report is available in either PDF format or as an Excel dataset, depending on the license you choose.
The PDF version provides the full analysis and visuals in a ready-to-read format. The Excel dataset includes all underlying data tables for easy manipulation and further analysis.
Please review the license options at checkout or contact us to confirm which formats are included with your purchase.
Our payment process is fully secure and PCI-DSS compliant.
We use trusted and encrypted payment gateways to ensure that all transactions are protected with industry-standard SSL encryption. Your payment details are never stored on our servers and are handled securely by certified third-party processors.
You can make your purchase with confidence, knowing your personal and financial information is safe with us.
Yes, we do offer special pricing for bulk purchases.
If you're interested in purchasing multiple reports, we’re happy to provide a customized bundle offer or volume-based discount tailored to your needs. Please contact our sales team with the list of reports you’re considering, and we’ll share a personalized quote.
Yes, absolutely.
Our team is available to help you make an informed decision. Whether you have questions about the report’s scope, methodology, customization options, or which license suits you best, we’re here to assist. Please reach out to us at sales@theinsightpartners.com, and one of our representatives will get in touch promptly.
Yes, a billing invoice will be automatically generated and sent to your registered email upon successful completion of your purchase.
If you need the invoice in a specific format or require additional details (such as company name, GST, or VAT information), feel free to contact us, and we’ll be happy to assist.
Yes, certainly.
If you encounter any difficulties accessing or receiving your report, our support team is ready to assist you. Simply reach out to us via email or live chat with your order information, and we’ll ensure the issue is resolved quickly so you can access your report without interruption.















- Sanofi
- GlaxoSmithKline plc
- Paxvax Inc
- Prokarium Ltd
- Scandinavian Biopharma


